Synthetic biology

Cancer research
#Cancer immunotherapy #Cancer research #Funding #Immunotherapy #Investment #ISA Pharmaceuticals #Oncology #Ophthalmology #Synthetic biology

$5 million to fund trial of therapy for uveal melanoma

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.  Cancer Focus Fund was established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and… Read More

#Business & Investment #Cancer Research #News

#Biologics / Biotechnology #Cell and gene therapy #Covid-19 #Drug discovery #mRNA-based vaccines #Plant-based #Synthetic biology #Ukraine

DDW’s best of 2022: What were your top reads?

2022 was a complicated year. Global challenges like the Ukraine war and the continued impact of Covid-19 have been felt across the world. And yet it was also a year of incredible innovation in drug discovery, with the potential of new biotechnology beginning to be revealed. Our top 10 most… Read More

#Editor's Choice #Exclusive Content #News

Enzymes
#Biologics / Biotechnology #Collaboration #Enzymes #High throughput screening #Partnership #Synthetic biology

Partnership hopes to accelerate protein discovery

GenScript Biotech, a provider of life-science research tools and services, is partnering with Allozymes, a Singapore-based biotech startup, with aims to accelerate the enzyme discovery and development process.  In the partnership, GenScript will provide the mutant libraries construction and expression, while Allozymes will provide ultra-high-throughput screening for… Read More

#News

#Drug discovery #Molecular Biology #Synthetic biology

Global advances in synthetic biology

Lu Rahman selects some recent synthetic biology innovations and the potential they hold to benefit drug discovery.  The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. Applying the principles of engineering to biology… Read More

#Exclusive Content

#3D cell culture #Automated workflows #Cell Science #Drug discovery #Organ-on-a-chip #Organoids #Synthetic biology

What an innovation centre means for 3D biology

DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids.  In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D… Read More

#Exclusive Content

Synthetic DNA
#AI #Antibodies #Biotechnology #Drug development #Drug discovery #Synthetic biology #Synthetic DNA #Synthetic libraries

Synthetic biology tools advancing and accelerating drug discovery efforts

Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery.  The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. It has made its… Read More

#Exclusive Content

#Biotechnology #Drug development #Drug discovery #Genomics #Synthetic biology #Synthetic DNA

Synthetic biology: Shaping the future of drug discovery 

By Lu Rahman  There are some exciting developments happening in synthetic biology and as a result the sector is highly attractive from an investment perspective. Using synthetic DNA to develop drugs and to better understand the toxic effects of them is a key driver for this market. BCC Research reports… Read More

#Exclusive Content #Trends & Analysis

#Biopharma #Biopharmaceuticals #DNA #Synthetic biology

Why synthetic biology is the next big thing for biopharma 

Listen to this article on the DDW Podcast: ‘Can synthetic biology save us?’ and ‘synthetic biology can benefit us all’, are just some of the headlines this emerging scientific field has recently elicited. Lu Rahman speaks to Dr Emily Leproust, Founder and CEO of Twist Biopharma, about the potential that synthetic biology holds within… Read More

#Exclusive Content

#Drug discovery #Microbiome #Synthetic biology

Stanford researchers construct the most complete synthetic microbiome

Listen to this article on the DDW Podcast: Rebecca McClellan, Scientific Program Manager, Research, Development & Communications, explains how scientists are learning more about the connections between the microbiome and human health to potentially develop first-in-class microbiome therapies. Key studies in the last decade have shown that the gut microbiome, the… Read More

#Exclusive Content

#Biopharma #DNA #Drug discovery #Evonetix #Synthetic biology

Synthetic biology: Advancing drug discovery

This eBook, sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery.   Key topics include:   Four key approaches to synthetic biology  The global advances in synthetic biology drug discovery Why synthetic biology is the next big… Read More

#DDW eBooks

#Biopharma #Drug discovery #Evonetix #Organoids #Synthetic biology

Synthetic biology e-book out now  

This e-book, sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery.   Key topics include:   Four key approaches to synthetic biology  The global advances in synthetic biology drug discovery Why synthetic biology is the next big… Read More

#News

#DNA #Drug discovery #Gene sequencing #Synthetic biology

A different approach: reimagining biology

Listen to this article on the DDW Podcast: Evonetix is reimaging biology by developing a different approach to gene synthesis. Three key members of the team - Dr Raquel Sanches-Kuiper, Vice President of Technology, Dr Matthew Hayes, Chief Technology Officer and John Edgell, Head of Cloud Engineering – explain how the… Read More

#Exclusive Content

#Business #Investment #Synthetic biology

Synthetic biology in UK gets £5.5m boost  

A UK centre for synthetic biology has received £5.5 million in funding so it can support start-ups and SMEs in the sector.  The UK’s National Centre for the Industrial Translation of Synthetic Biology, SynbiCITE, will use the funding to support businesses within the sector and to help… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Immunotherapy #Synthetic biology

The summer issue of Drug Discovery World magazine is out now 

Featuring Specialty Spotlight: Immunotherapy, the magazine is available to download and read for free on the DDW App. Key features of the summer issue include: Why immunocompromised people are ‘forgotten’: Championing female leaders across drug discovery and development: Improving quality control for CAR T cell therapies, plus exclusive interviews and articles on… Read More

#News #Trending News

#Appointment #DNA #Synthetic biology

Evonetix appoints new CEO to support DNA platform  

Synthetic biology company Evonetix has appointed a new Chief Executive Officer (CEO) to support the company’s next phase of product development.   The company has appointed Colin McCracken as CEO with immediate effect. McCracken has over 20 years of experience and will support Evonetix in the development and… Read More

#News

#Biopharma #Synthetic biology

Evonetix granted patent for DNA synthesis tech 

Synthetic biology company Evonetix’ has been granted a patent in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips.  The EP3551331B1 patent will extend Evonetix’s IP portfolio and will help the company stratetgy’s for developing… Read More

#News